

FW

Atty. Dkt. No. 034536-1595

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gregory D. PLOWMAN et al.
Title: DIAGNOSIS AND TREATMENT OF ALK-7 RELATED DISORDERS
Appl. No.: 10/849,518
Filing Date: 05/20/2004
Examiner: Unassigned
Art Unit: Unassigned

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The USPTO has waived the requirement under 37 CFR 1.98(a)(2)(i) to submit copies of U.S. patents and U.S. patent application publications when citing and submitting an Information Disclosure Statements in a patent application filed after June 30, 2003 and in an international application that has entered the national stage under 37 USC §371 after June 30, 2003. Accordingly, copies of these types of documents are not being supplied in connection with this application. Reference is being made to OG Notice dated August 5, 2003, *Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003.*

Applicants submit herewith on Form PTO/SB/08 a listing of the documents cited by or submitted to the U.S. PTO in parent application Serial No. 09/069,228, filed 04/27/1998. As provided in 37 CFR §1.98(d), copies of the documents are not being provided since they were previously submitted to the United States Patent & Trademark Office in the above-identified parent application.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.


TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), before the mailing date of the first Office Action on the merits.

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,


Date 16 September 2004 By 

FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/849,518
				Filing Date	05/20/2004
				First Named Inventor	Gregory D. PLOWMAN
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	14	Attorney Docket Number	034536-1595



U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	4,343,940		KREIGHBAUM et al.	08-10-1982	
	A2	4,376,110		DAVID et al.	03-08-1983	
	A3	4,447,608		JONES et al.	05-08-1984	
	A4	4,757,072		KABBE et al.	07-12-1988	
	A5	4,945,050		SANFORD et al.	07-31-1990	
	A6	5,168,050		HAMMONDS, JR. et al.	12-01-1992	
	A7	5,217,999		LEVITZKI et al.	06-08-1993	
	A8	5,283,173		FIELDS et al.	02-01-1994	
	A9	5,302,606		SPADA et al.	04-12-1994	
	A10	5,316,553		KAUL et al.	05-31-1994	
	A11	5,330,992		EISSENSTAT et al.	07-19-1994	
	A12	5,602,171		TANG et al.	02-11-1997	
	A13	5,614,609		IBANEZ et al.	03-25-1997	
	A14	5,789,565		IBANEZ et al.	08-04-1998	
	A15	5,811,245		IBANEZ et al.	09-22-1998	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/849,518
				Filing Date	05/20/2004
				First Named Inventor	Gregory D. PLOWMAN
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
				Attorney Docket Number	034536-1595
Sheet	2	of	14		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	A16	EP	0 520 722	A1	ICI PLC	12-30-1992		
	A17	EP	0 566 226	A1	ZENECA LTD	10-20-1993		
	A18	EP	0 562 734	A1	ZENECA LTD	09-29-1993		
	A19	WO	91/15495	A1	PFIZER INC.	10-17-1991		
	A20	WO	92/20642	A1	RHONEPOULENC RORER INTERNATIONAL INC.	11-26-1992		
	A21	WO	92/21660	A1	PFIZER INC.	12-10-1992		
	A22	WO	93/09236	A1	BAYLOR COLLEGE OF MEDICINE	05-13-1993		
	A23	WO	93/10242	A1	COLD SPRING HARBOR LABORATORY	05-27-1993		
	A24	WO	94/01119	A1	NATIONAL UNIVERSITY OF SINGAPORE	01-20-1994		
	A25	WO	94/14808	A1	FARMITALIA CARLO ERBA S.R.L.	07-07-1994		
	A26	WO	94/23039	A1	THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL	10-13-1994		
	A27	WO	95/06735	A2	THE LUDWIG INSTITUTE FOR CANCER RESEARCH	03-09-1995		
	A28	WO	96/34985	A1	PHARMACIA S.P.A.	08-01-1996		
	A29	WO	96/34985	A1	SUGEN, INC.	11-07-1996		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/849,518		
		Filing Date	05/20/2004		
		First Named Inventor	Gregory D. PLOWMAN		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	3	of	14	Attorney Docket Number	034536-1595

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A30	ABE et al., "Molecular Characterization of a Novel Metabotropic Glutamate Receptor mGluR5 Coupled to Inositol Phosphate/Ca ²⁺ Signal," <u>J. Biol. Chem.</u> , 1992, PP. 13361-13368, Vol. 267, No. 19	
	A31	Accession number AR021339 on GenEmbl database, December 1998	
	A32	ALLEN et al., "Modulation of CD4 by suramin," <u>Clin. Exp. Immunol.</u> , 1991, pp. 141-146, Vol. 91	
	A33	ALTSCHUL et al., "Basic Local Alignment Search Tool," <u>J. Mol. Biol.</u> , 1990, pp. 403-410, Vol. 215	
	A34	ANAFI et al., "Tyrphostin-Induced Inhibition of p210 ^{bcr-abl} Tyrosine Kinase Activity Induces K562 to Differentiate," <u>Blood</u> , 1993, pp. 3524-3529, Vol. 82	
	A35	AOKI et al., "The Novel Protein-Tyrosine Phosphatase PTP20 is a Positive Regulator of PC12 Cell Neuronal Differentiation," <u>J. Biol. Chem.</u> , 1996, pp. 29422-29426, Vol. 271, No. 461	
	A36	AUSUBEL et al., "Tyrphostin-Induced Inhibition of p210 ^{bcr-abl} Tyrosine Kinase Activity Induces K562 to Differentiate," <u>Blood</u> , 1993, pp. 3524-3529, Vol. 82	
	A37	BAKER et al., "Induction of acetylcholine receptor clustering by native polystyrene beads," <u>Journal of Cell Science</u> , 1992, pp. 543-555, Vol. 102	
	A38	BARKER et al., "In vitro activity of non-glutamate containing quinazoline-based thymidylate synthase inhibitors," <u>Proceedings of the American Association for Cancer Research</u> , 1991, p. 327 at abstract No. 1939, Vol. 32	
	A39	BASSING et al., "A Transforming Growth Factor β Type I Receptor that Signals to Activate Gene Expression," <u>Science</u> , 1994, p. 87, Vol. 263	
	A40	BAYER et al., "The Avidin-Biotin Complex in Affinity Cytochemistry," <u>Methods in Enzymology</u> , 1979, pp. 308-319, Vol. 62	
	A41	BENOIST et al., "In vivo sequence requirements of the SV40 early promoter region," <u>Nature</u> , 1981, pp. 304-310, Vol. 290	
	A42	BERTINO et al., "Toward improved selectivity in cancer chemotherapy: the Richard and Hinda Rosenthal Foundation Award Lecture," <u>Cancer Research</u> , 1979, pp. 293-304, Vol. 39	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/849,518
		Filing Date	05/20/2004
		First Named Inventor	Gregory D. PLOWMAN
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	4	of	14
		Attorney Docket Number	034536-1595

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A43	BIGNER et al., "Structural chromosomal abnormalities in human medulloblastoma," <u>Cancer Genet. Cytogenet.</u> , 1988, pp. 91-101, Vol. 30	
	A44	BILDER et al., "Tyrophostins inhibit PDGF-induced DNA synthesis and associated early events in smooth muscle cells," <u>Am. J. Physiol.</u> , 1991, pp. C721-C730, Vol. 260, Vol. 29	
	A45	BOLLON et al., "DNA transformation efficiency of various bacterial and yeast host-vector systems," <u>Journal of Clinical Hematology and Oncology</u> , 1980, pp. 39-487, Vol. 10, Nos. 2 & 3	
	A46	BOTSTEIN et al., "Making mutations in vitro and putting them back into yeast," <u>Miami Winter Symposia -- From Gene to Protein: Translation into Biotechnology</u> , edited by Ahmad et al., 1982, pp. 265-274, Vol. 19, Academic Press	
	A47	BRINSTER et al., "Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs," <u>Proc. Natl. Acad. Sci. USA</u> , 1985, pp. 4438-4442, Vol. 82	
	A48	BROACH et al., "The Yeast Plasmid 2 μ Circle," <u>Cell</u> , 1982, pp. 203-204, Vol. 28	
	A49	BROACH, <u>The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance</u> , 1981, pp. 445-470, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY	
	A50	BRUNTON et al., "Anti-tumour activity of novel tryphostins in breast cancer cells," <u>Proceeding of the American Association for Cancer Research</u> , 1992, p. 558 at abstract no. 3335, Vol. 33	
	A51	BRYCKAERT et al., <u>Experimental Cell Research</u> , 1992, pp. 255-261, Vol. 199	
	A52	BULLOCK et al., <u>Techniques in Immunocytochemistry</u> , Vol. 1 (1982), Vol. 2 (1982), Vol. 3 (1985), Academic Press, Orlando, FL (TABLE OF CONTENTS ONLY)	
	A53	BURKE et al., "Arylamides of Hydroxylated Isoquinolines as Protein-Tyrosine Kinase Inhibitors," <u>Bioorganic & Medical Chemistry Letters</u> , 1992, pp. 1771-1774, Vol. 2, No. 12	
	A54	BURKE et al., "Bicyclic Compounds as Ring-Constrained Inhibitors of Protein-Tyrosine Kinase p56 ^{lck} 1," <u>Journal of Medicinal Chemistry</u> , 1993, pp. 425-432, Vol. 36, No. 4	
	A55	CAMPBELL, <u>Monoclonal Antibody Technology: Laboratory Techniques in Biochemistry and Molecular Biology</u> , Elsevier Science Publishers, Amsterdam, The Netherlands, 1984	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/849,518		
		Filing Date	05/20/2004		
		First Named Inventor	Gregory D. PLOWMAN		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	5	of	14	Attorney Docket Number	034536-1595

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A56	CAPECCHI, "Altering the Genome by Homologous Recombination," <u>Science</u> , 1989, pp. 1288-1292, Vol. 244	
	A57	CAPECCHI, "High Efficiency Transformation by Direct Microinjection of DNA into Cultured Mammalian Cells," <u>Cell</u> , 1980, pp. 479-488, Vol. 22	
	A58	CENATIEMPO, "Prokaryotic Gene Expression In Vitro: Transcription - Translation Coupled Systems," <u>Biochimie</u> , 1986, pp. 505-516, Vol. 68	
	A59	CHARD, <u>An Introduction to Radioimmunoassay and Related Techniques</u> , 1986, Elsevier Science Publishers, Amsterdam, The Netherlands	
	A60	CHATER et al., <u>Sixth International Symposium on Actinomycetales Biology</u> , 1986, pp. 45-54, Akademiai Kiado, Budapest, Hungary	
	A61	CHEN, "High-Efficiency Transformation of Mammalian Cells by Plasmid DNA," <u>Molecular and Cellular Biology</u> , 1987, pp. 2745-2754, Vol. 7, No. 8	
	A62	CHOMCZYNSKI et al., "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Chloroform Extraction," <u>Analytical Biochemistry</u> , 1987, pp. 156-159, Vol. 162	
	A63	CHU et al., "Electroporation for the efficient transfection of mammalian cells with DNA," <u>Nucleic Acids Research</u> , 1987, pp. 1311-1326, Vol. 15	
	A64	CURIEL et al., "Adenovirus Enhancement of Transferring-Polylysine-Mediated Gene Delivery," <u>Proc. Natl. Acad. Sci. USA</u> , October 1991, pp. 247-252, Vol. 6	
	A65	CURIEL et al., "Gene Transfer to Respiratory Epithelial Cells via the Receptor-mediated Endocytosis Pathway," <u>Am. J. Respir. Cell. Mol. Biol.</u> , 1992, pp. 247-252, Vol. 6	
	A66	CURTIN et al., "Inhibition of the growth of human hepatocellular carcinoma in vitro and in athymic mice by a quinazoline inhibitor of thymidylate synthase, CB3717," <u>Br. J. Cancer</u> , 1986, pp. 361-368, Vol. 53	
	A67	DIJKE et al., "Activin Receptor-like Kinases: A Novel Subclass of Cell-Surface Receptors with Predicted Serine/Threonine Kinase Activity," <u>Oncogene</u> , 1993, p. 2879, Vol. 8	
	A68	DOLLE et al., "5,7-Dimethoxy-3-(4-pyridinyl)auinoline is a Potent and Selective Inhibitor of Human Vascular - Type Platelet - Derived Growth Factor Receptor Tyrosine Kinase," <u>J. Med. Chem.</u> , 1994, pp. 2627-2629, Vol. 37	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/849,518
				Filing Date	05/20/2004
				First Named Inventor	Gregory D. PLOWMAN
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	6	of	14	Attorney Docket Number	034536-1595

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		
	A69	DONG et al., "Protein Tyrosine Kinase Inhibitors Decrease Induction of Nitric Oxide Synthase Activity in Lipopolysaccharide-Responsive and Lipopolysaccharide-Nonresponsive Murine Macrophages," <u>The Journal of Immunology</u> 151(5):2717-2724 (1993).		
	A70	DONG et al., "Activation of tumoricidal properties in macrophages by lipopolysaccharide requires protein – tyrosine kinase activity," <u>Journal of Leukocyte Biology</u> , 1993, pp. 53-60, Vol. 53		
	A71	ECK et al., "Gene-Based Therapy," <u>The Pharmacological Basis of Therapeutics</u> , Goodman and Gilman, Eds., 1996, pp. 77-101		
	A72	ENGVALL and PERLMANN, "Enzyme-Linked Immunosorbent Assay, ELISA. III. Quantitation of Specific Antibodies by Enzyme-Labeled Anti-Immunoglobulin in Antigen-Coated Tubes," <u>J. Immunology</u> 109:129-135 (1972) (mistakenly referred to as Engval).		
	A73	FELGNER and RINGOLD, "Cationic liposome-mediated transfection," <u>Nature</u> 337:387-388 (1989).		
	A74	FELGNER et al., "Lipofection: A Highly Efficient, Lipid-mediated DNA-transfection Procedure," <u>Proc. Natl. Acad. Sci. USA</u> 84:7413-7417 (1987).		
	A75	FERNANDES et al., "Biochemical and Antitumor Effects of 5,8-Dideazaisopteroylglutamate, a Unique Quinazoline Inhibitor of Thymidylate Synthase," <u>Cancer Research</u> 43:1117-1123 (1983).		
	A76	FERRIS et al., "Synthesis of Quinazoline Nucleosides from Ribose and Anthranilonitrile. Application of Phase-Transfer Catalysis in Nucleoside Synthesis," <u>J. Org. Chem.</u> 44(2):173-178 (1979).		
	A77	FIELDS et al., "Cell Surface Markers for Distinguishing Different Types of Rat Dorsal Root Ganglion Cells in Culture," <u>Cell</u> , 1978, p. 43, Vol. 14		
	A78	FINGL and WOODBURY, "Chapter 1- General Principles," in <u>The Pharmacological Basis of Therapeutics</u> , 5 th Edition, Goodman and Gilman, Eds., MacMillan Publishing Co., Inc. New York, pp. 1-46, 1975		
	A79	FRANZEN et al., "Cloning of a TGFβ Type I Receptor that Forms a Heteromeric Complex with the TGFβ Type II Receptor," <u>Cell</u> , 1993, p. 681, Vol. 75, No. 4		
	A80	FRY et al., "A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase," <u>Science</u> 265:1093-1095 (1994).		
	A81	GAZIT et al., "Tyrphostins 1. Synthesis and Biological Activity of Protein Tyrosine Kinase Inhibitors," <u>J. Med. Chem.</u> 32:2344-2352 (1989).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Complete if Known	
		Application Number	10/849,518
(use as many sheets as necessary)		Filing Date	05/20/2004
		First Named Inventor	Gregory D. PLOWMAN
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	7	of	14
		Attorney Docket Number	034536-1595

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A82	GAZIT et al., "Tyrphostins. 3. Structure-Activity Relationship Studies of a -Substituted Benzylidenemalononitrile 5-S-Aryltyrphostins," <u>J. Med. Chem.</u> 36:3556-3564 (1993).	
	A83	GILMAN et al., "Isolation of sigma-28-specific promoters from Bacillus subtilis DNA," <u>Gene</u> 32:11-20 (1984).	
	A84	GLICK and WHITNEY, "Factors affecting the expression of foreign proteins in Escherichia coli," <u>Journal of Industrial Microbiology</u> 1:277-282 (1987).	
	A85	GODING, "Conjugation of Antibodies with Fluorochromes: Modifications to the Standard Methods," <u>J. Immunological Methods</u> 13:215-226 (1976).	
	A86	GOLD et al., "Translational Initiation in Prokaryotes," <u>Ann. Rev. Microbiol.</u> 35:365-403 (1981).	
	A87	GOTTESMAN, "Bacterial Regulation: Global Regulatory networks," <u>Ann. Rev. Genet.</u> 18:415-441 (1984).	
	A88	GRAHAM et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5," <u>J. of Gen. Virology</u> , 1977, pp. 59-72, Vol. 36	
	A89	GREENE et al., "PC12 Pheochromocytoma Cells: Culture, Nerve Growth Factor Treatment, and Experimental Exploitation," <u>Methods Enzymol.</u> , 1987, p. 207, Vol. 147	
	A90	HAMMER and WALLING, "Regulation In Vivo of a Cloned Mammalian Gene: Cadmium Induces the Transcription of a Mouse Metallothionein Gene in SV40 Vectors," <u>J. of Molecular and Applied Genetics</u> 1:273-288 (1982).	
	A91	HAMMER et al., "Spontaneous Inflammatory Disease in Transgenic Rats Expressing HLA-B27 and Human B2m: An Animal Model of HLA-B27-Associated Human Disorders," <u>Cell</u> 63:1099-1112 (1990).	
	A92	HANKS and HUNTER, "The Eukaryotic Protein Kinase Superfamily: Kinase (Catalytic) Domain Structure and Classification," <u>FASEB J.</u> , 1995, pp. 576-595, Vol. 9	
	A93	HARTMANN et al., "Predicting the Orientation of Eukaryotic Membrane-Spanning Proteins," <u>Proc. Natl. Acad. Sci. USA</u> , 1989, p. 5786, Vol. 86	
	A94	HASLAM et al., "Pleckstrin Domain Homology," <u>Nature</u> , 1993, p. 309, Vol. 363	

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/849,518		
		Filing Date	05/20/2004		
		First Named Inventor	Gregory D. PLOWMAN		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	8	of	14	Attorney Docket Number	034536-1595

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	A95	HAWROT and PATTERSON, "Long-Term Culture of Dissociated Sympathetic Neurons," in <u>Methods in Enzymology – Cell Culture</u> , Jakoby and Pastan Eds., Academic Press, New York, NY, 1979, pp. 574-584		
	A96	HELDIN, "Dimerization of Cell Surface Receptors in Signal Transduction," <u>Cell</u> , 1995, pp. 213-233, Vol. 80		
	A97	HOUEBINE and CHOURROUT, "Trangensis in Fish," <u>Experientia</u> 47:891-897 (1991).		
	A98	HOUEBINE, <u>Journal of Biotechnology</u> , 1994, pp. 269-287, Vol. 34		
	A99	HURBY et al., "Application of Synthetic Peptides: Antisense Peptides," in <u>Synthetic Peptides, A User's Guide</u> , W.H. Freeman, NY pp. 289-307 (1992), Grant G. (ed.).		
	A100	INNIS et al., <u>PCR Protocols: A Guide to Methods and Applications</u> , edited by Michael A. Innis et al., Academic Press, San Diego (1990) (Table of Contents Only).		
	A101	IZAKI, <u>Japanese Journal of Bacteriology</u> 33(6):729-742 (1978).		
	A102	JACKMAN, "ICI D1694, a Quinazoline Antifolate Thymidylate Synthase Inhibitor That Is a Potent Inhibitor of L1210 Tumor Cell Growth in Vitro and in Vivo: A New Agent for Clinical Study," <u>Cancer Research</u> 51:5579-5586 (1991).		
	A103	JAKOBY and WILCHEK (editors), <u>Affinity Techniques: Enzyme Purification: Part B, Methods in Enzymology</u> , Vol. XXXIV, Academic Press, New York (1974) (Table of Contents Only).		
	A104	JASNY, "Insect Viruses Invade Biotechnology," <u>Science</u> 238:1653 (1987).		
	A105	JOHN and TWITTY, "Plasmids as Epidemiologic Markers in Nosocomial Gram-Negative Bacilli: Experience at a University and Review of the Literature," <u>Reviews of Infectious Diseases</u> 8:693-704 (1986).		
	A106	JOHNSTON and HOPPER, "Isolation of the yeast regulatory gene GAL4 and analysis of its dosage effects on the galactose/melibiose regulon," <u>Proc. Natl. Acad. Sci. USA</u> 79:6971-6975 (1982).		
	A107	JONES et al., "Quinazoline Antifolates Inhibiting Thymidylate Synthase: Variation of the Amino Acid," <u>J. Med. Chem.</u> 29:1114-1118 (1986).		
	A108	JOYNER et al., "Production of a mutation in mouse En-2 gene by homologous recombination in embryonic stem cells," <u>Nature</u> 338:153-156 (1989).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/849,518		
		Filing Date	05/20/2004		
		First Named Inventor	Gregory D. PLOWMAN		
		Group Art Unit	Unassigned		
Examiner Name	Unassigned				
Sheet	9	of	14	Attorney Docket Number	034536-1595

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A109	KASPRZAK et al., "Location of a Contact Site Between Actin and Myosin in the Three-Dimensional Structure of the Acto-S1 Complex," <u>Biochemistry</u> 28:9230-9238 (1989) (also referred to as Kaspczak).	
	A110	KAUR, "Tyrphostin induced growth inhibition: correlation with effect on p210.sup.bcr-abl autokinase activity in K562 chronic myelogenous leukemia," <u>Anti-Cancer Drugs</u> 5:213-222 (1994).	
	A111	KENDALL and COHEN, "Plasmid Transfer in Streptomyces lividans: Identification of a kil-kor System Associated with the Transfer Region of PIJ101," <u>Journal of Bacteriology</u> 169:4177-4183 (1987).	
	A112	KING et al., "Site-specific dephosphorylation and deactivation of the human insulin receptor tyrosine kinase by particulate and soluble phosphotyrosyl protein phosphatases," <u>Biochem. J.</u> 275:413-418 (1991).	
	A113	KLEIN et al., "The Detection and Classification of Membrane-Spanning Proteins," <u>Biochim. Biophys. Acta</u> , 1985, p. 468, Vol. 815	
	A114	KOHLER and MILSTEIN, "Continuous cultures of fused cells secreting antibody of predefined specificity," <u>Nature</u> 256:495-497 (1975).	
	A115	KUO et al., "Effects of signalling transduction modulators on the transformed phenotypes in v-H-ras-transformed NIH 3T3 cells," <u>Cancer Letters</u> 74:197-202 (1993).	
	A116	LEE and SKIBO, "Active-Site-Directed Reductive Alkylation of Xanthine Oxidase by Imidazo[4,5-g]quinazoline-4,9-diones Functionalized with a Leaving Group," <u>Biochemistry</u> 26:7355-7362 (1987).	
	A117	LEMUS et al., "Studies of Extended Quinone Methides. Synthesis and Physical Studies of Purine-like Monofunctional and Bifunctional Imidazo[4,5-g]quinazoline Reductive Alkylating Agents," <u>J. Org. Chem.</u> 54:3611-3618 (1989).	
	A118	LEVITZKI, "Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction," <u>FASEB J.</u> 6:3275-3282 (1992).	
	A119	LEY and SENG, "Synthesis Using Benzofuroxan," <u>Synthesis</u> 1975:415-422 (1975).	
	A120	LUTZ et al., "The Distribution of Two hnRNP-Associated Proteins Defined by a Monoclonal Antibody Is Altered in Heat-Shocked HeLa Cells," <u>Experimental Cell Research</u> 175:109-124 (1988).	
	A121	LYALL et al., "Tyrphostins Inhibit Epidermal Growth Factor (EGF)-Receptor Tyrosine Kinase Activity in Living Cells and EGF-stimulated Cell Proliferation," <u>J. Biol. Chem.</u> 264:14503-14509 (1989).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/849,518		
		Filing Date	05/20/2004		
		First Named Inventor	Gregory D. PLOWMAN		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	10	of	14	Attorney Docket Number	034536-1595

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A122	MAEKAWA et al., "Molecular Cloning of a Novel Protein-Tyrosine Phosphatase Containing a Membrane-Binding Domain and glgf Repeats," <u>FEBS LETTERS</u> , 1994, pp. 200-206, Vol. 337	
	A123	MAGUIRE et al., "A new series of PDGF Receptor Tyrosine Kinase Inhibitors: 3-Substituted Quinoline Derivatives," <u>J. Med. Chem.</u> , 1994, pp. 2129-2137, Vol. 37	
	A124	MANIATIS, In: <u>Cell Biology: A Comprehensive Treatise</u> , vol. 3, <u>Gene Sequence Expression</u> , Academic Press, NY, pp. 563-608 (1980).	
	A125	MASSAGUE, "The TGF- β Family and its Composite Receptors," <u>Trends Cell Biol.</u> , 1994, p. 172, Vol. 4	
	A126	MATTHEWS et al., "Characterization of Hematopoietic Intracellular Protein Tyrosine Phosphatases: Description of a Phosphatase Containing an SH2 Domain and Another Enriched in Proline-, Glutamic Acid-, Serin-, and Threonine-rich Sequences," <u>Mol. Cell. Biol.</u> , 1992, pp. 2396-2405, Vol. 12, No. 5	
	A127	MAXWELL et al., ".sup.19 F Nuclear Magnetic Resonance Imaging of Drug Distribution in Vivo: The Disposition of an Antifolate Anticancer Drug in Mice," <u>Magnetic Resonance in Medicine</u> 17:189-196 (1991).	
	A128	MAYER et al., "A novel viral oncogene with structural similarity to phospholipase C," <u>Nature</u> , 1988, pp. 272-275, Vol. 332	
	A129	McGEOCH, "On the Predictive Recognition of Signal Peptide Sequences," <u>Virus Research</u> , 1985, p. 271, Vol. 3	
	A130	McKNIGHT, "Functional Relationships between Transcriptional Control Signals of the Thymidine Kinase Gene of Herpes Simplex Virus," <u>Cell</u> 31:355-365 (1992).	
	A131	MILLAUER et al., "Glioblastoma growth inhibited <i>in vivo</i> by a dominant-negative Flk-1 mutant," <u>Nature</u> , 1994, pp. 576-579, Vol. 367	
	A132	MILLER et al., In: <u>Genetic Engineering</u> , Vol. 8, Plenum, Setlow et al., eds., pp. 277-297 (1986).	
	A133	MILLER, "Human gene therapy comes of age," <u>Nature</u> 357:455-460 (1992).	
	A134	MINI et al., "Cytotoxic Effects of Folate Antagonists against Methotrexate-resistant Human Leukemic Lymphoblast CCRF-CEM Cell Lines," <u>Cancer Research</u> 45:325-330 (1985).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/849,518
				Filing Date	05/20/2004
				First Named Inventor	Gregory D. PLOWMAN
				Group Art Unit	Unassigned
Examiner Name	Unassigned				
Attorney Docket Number	034536-1595				
Sheet	11	of	14		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	A135	MULLIGAN, "The Basic Science of Gene Therapy," <u>Science</u> 260:926-932 (1993).		
	A136	NELSON, "Detection of Acridinium Esters by Chemiluminescence," <u>Nonisotopic DNA Probe Techniques</u> , ed. Larry J. Kricka, (San Diego:Academy Press, Inc.) pp. 275-310 (1992) (Table of Contents Only).		
	A137	OKAYAMA and BERG, "A cDNA Cloning Vector That Permits Expression of cDNA Inserts in Mammalian Cells," <u>Molecular and Cellular Biology</u> 3:280-289 (1983).		
	A138	ORKIN et al., "Report and Recommendation of the Panel to Assess the NIH Investment in Research on Gene Therapy," NIH, 1995		
	A139	PATI, "Novel vectors for expression of cDNA encoding epitope-tagged proteins in mammalian cells," <u>Gene</u> 114:2856-288 (1992).		
	A140	PAWSON and SCHLESSINGER, "SH2 and SH3 domains," <u>Current Biology</u> , 1993, pp. 434-442, Vol. 3, No. 7		
	A141	PETERSON and BARNES, "Genistein and Biochanin A Inhibit the Growth of Human Prostate Cancer Cells but not Epidermal Growth Factor Receptor Tyrosine Autophosphorylation," <u>The Prostate</u> 22:335-345 (1993).		
	A142	PHILLIPS and CASTLE, "Quino[1,2-c]quinazolines. I. Synthesis of Quino[1,2-c]quinazolinium Derivatives and the Related Indazolo[2,3-a]quinoline Derivatives as Analogs of the Antitumor Benzo[c]phenanthridine Alkaloids," <u>J. Heterocyclic Chemistry</u> 17:1489-1496 (1980).		
	A143	PILLEMER et al., "Insulin Dependence of Murine Lymphoid T-Cell Leukemia," <u>Brit. J. Cancer</u> 50:80-85 (1992).		
	A144	PONTING, "Pleckstrin's Repeat Performance: A Novel Domain in G-protein Signaling," <u>TIBS</u> , 1996, p. 245, Vol. 21		
	A145	POSNER et al., "Kinetics of inhibition by Tyrphostins of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor and Analysis by a New Computer Program," <u>Molecular Pharmacology</u> 45:673-683 (1993).		
	A146	PURSEL et al., "Genetic Engineering of Livestock," <u>Science</u> 244:1281-1288 (1989).		
	A147	REECE et al., "Pharmacokinetics of Trimetrexate Administered by Five-Day Continuous Infusion to Patients with Advanced Cancer," <u>Cancer Research</u> 47:2996-2999 (1987).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/849,518
				Filing Date	05/20/2004
				First Named Inventor	Gregory D. PLOWMAN
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	12	of	14	Attorney Docket Number	034536-1595

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ⁶
	A148	<u>Remington's Pharmaceutical Sciences</u> , 1990, 18 th ed., Mack Publishing Col., Easton, PA		
	A149	RENDU et al., "Inhibition of Platelet Activation by Tyrosine Kinase Inhibitors," <u>Biochemical Pharmacology</u> 44(5):881-888 (1992).		
	A150	ROBERTSON, E.J., ed., <u>Teratocarcinomas and Embryonic Stem Cells, A Practical Approach</u> , IRL Press (1987).		
	A151	RUBIN, "Drosophila melanogaster as an Experimental Organism," <u>Science</u> 240:1453-1459 (1988).		
	A152	RYDEN et al., "A novel type I receptor serine-threonine kinase predominantly expressed in the adult central nervous system," <u>J. Biol. Chem.</u> , November 1996		
	A153	RYDEN et al., "A Novel Type I Receptor Serine-Threonine Kinase Predominantly Expressed in the Adult Central Nervous System," <u>J. Biol. Chem.</u> , 1996, p. 30603, Vol. 271		
	A154	SADOWSKI et al., "A Noncatalytic Domain Conserved Among Cytoplasmic Protein-Tyrosine Kinases Modifies the Kinase Function and Transforming Activity of Fujinami Sarcoma Virus P130 ^{gag-fps} ," <u>Molecular and Cellular Biology</u> , 1986, pp. 4396-4408, Vol. 6, No. 12		
	A155	SAMBROOK, FRITSCH & MANIATIS, eds., <u>Molecular Cloning: A Laboratory Manual</u> , second edition, Cold Spring Harbor Laboratory (1989).		
	A156	SARAS et al., "Cloning and Characterization of PTPL1, A Protein Tyrosine Phosphatase with Similarities to Cytoskeletal-Associated Proteins," <u>J. Biol. Chem.</u> , 1994, pp. 24082-24089, Vol. 269, No. 39		
	A157	SAURO and THOMAS, "Decreased Sensitivity of Aorta from Hypertensive Rats to Vasorelaxation by Tyrphostin," <u>Life Sciences</u> 53:PL371-376 (1993).		
	A158	SAURO and THOMAS, "Tyrphostin Attenuates Platelet-Derived Growth Factor-Induced Contraction in Aortic Smooth Muscle Through Inhibition of Protein Tyrosine Kinase(s)," <u>The Journal of Pharmacology and Experimental Therapeutics</u> 267:1119-1125 (1993).		
	A159	SCULIER et al., "Role of an Intensive Care Unit (ICU) in a Medical Oncology Department," <u>Cancer Immunol. and Immunotherapy</u> 23:A65 at abstract No. 257 (1986).		
	A160	SHIMODA et al., "A High Percentage Yield of Tyrosine Hydroxylase-positive Cells from Rat E14 Mesencephalic Cell Culture," <u>Brain Research</u> , 1992, pp. 319-331, Vol. 586		

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/849,518		
		Filing Date	05/20/2004		
		First Named Inventor	Gregory D. PLOWMAN		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	13	of	14	Attorney Docket Number	034536-1595

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A161	SIKORA and GRZELAKOWSKA-SZTABERT, "Quinazoline CB 3717 and CB 3703 Inhibitors of Folate Retention and Metabolism in Ehrlich Ascites Carcinoma Cells and Some Organs of the Host-Mouse," <u>Cancer Letters</u> 23:289-295 (1984).	
	A162	SIKORA et al., "Development of an Assay for the Estimation of N.sup.10 -Propargyl-5,8-dideazafolic Acid Polyglutamates in Tumor Cells," <u>Analytical Biochemistry</u> 172:344-355 (1988).	
	A163	SILVER et al., "Amino terminus of the yeast GAL4 gene product is sufficient for nuclear localization," <u>Proc. Natl. Acad. Sci. USA</u> 81:5951-5955 (1984).	
	A164	SIMONS et al., "Gene Transfer into Sheep," <u>Bio/Technology</u> 6:179-182 (1988) (also referred to as Simms or Simmons).	
	A165	SINGER, "The Structure and Insertion of Integral Proteins in Membranes," <u>Ann. Rev. Cell Biol.</u> , 1990, p. 247, Vol. 6	
	A166	ST. GROTH and SCHEIDEGGER, "Production of Monoclonal Antibodies: Strategy and Tactics," <u>J. Immunol. Methods</u> 35:1-21 (1980).	
	A167	STERNBERGER et al., "The Unlabeled Antibody Enzyme Method of Immunohistochemistry: Preparation and Properties of Soluble Antigen-Antibody Complex (Horseradish Peroxidase-Antihorseradish Peroxidase) and Its Use in Identification of Spirochetes," <u>J. Histochemistry and Cytochemistry</u> 18(5):315-333 (1970) (mistakenly referred to as Stemberger).	
	A168	STRAUSBERG, "National Cancer Institute, Cancer Genome Anatomy Project," <u>EMBL Database</u> , entry HS1185621; accession number AA281242, 1997	
	A169	TABOR et al., "DNA sequence analysis with a modified bacteriophage T7 DNA polymerase," <u>Proc. Natl. Acad. Sci. USA</u> 84:4767-4771 (1987).	
	A170	TIJSEN, "Practice and Theory of Enzyme Immunoassays: Laboratory Techniques in Biochemistry and Molecular Biology," Elsevier Science Publishers, Amsterdam, The Netherlands (1985).	
	A171	TSUCHIDA et al., "Molecular Cloning of a Novel Type I Receptor Serine/Theonine Kinase for the TGFβ Superfamily from Rat Brain," <u>Molec. Cell. Neurosci.</u> , 1996, p. 467, Vol. 7	
	A172	ULMANEN et al., "Transcription and Translation of Foreign Genes in Bacillus subtilis by the Aid of a Secretion Vector," <u>Journal of Bacteriology</u> 162:176-182 (1985).	
	A173	VERMA et al., <u>Nature</u> , 1997, pp. 239-242, Vol. 389	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/849,518		
		Filing Date	05/20/2004		
		First Named Inventor	Gregory D. PLOWMAN		
		Group Art Unit	Unassigned		
		Examiner Name	Unassigned		
Sheet	14	of	14	Attorney Docket Number	034536-1595

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	A174	VOEIKOVA et al., <u>Biotekhnologiya</u> , 1988, pp. 176-182, Vol. 4, ABSTRACT ONLY	
	A175	von HEIJNE, "A New Method for Predicting Signal Sequence Cleavage Sites," <u>Nucleic Acids Research</u> , 1986, pp. 4683-4691, Vol. 14, No. 11	
	A176	WARD et al., "Construction and characterisation of a series of multi-copy promoter-probe plasmid vectors for Streptomyces using the aminoglycoside phosphotransferase gene from Tn5 as indicator," <u>Mol. Gen. Genet.</u> 203:468-478 (1986).	
	A177	WEIR (eds), "Ch. 10--The chemistry and standardization of allergens," in <u>Handbook of Experimental Immunology--Volume 1: Immunochemistry</u> , 4th Ed., edited by Weir et al., Blackwell Scientific Publications, Oxford, England, pp. 10.1-10.28 (1986).	
	A178	WOLBRING et al., "Inhibition of GTP-utilizing Enzymes by Tyrphostins," <u>J. Biol. Chem.</u> 269:22470-22472 (1994).	
	A179	WRANA et al., "Mechanism of Activation of the TGF- β Receptor," <u>Nature</u> , 1994, pp. 341-347, Vol. 370	
	A180	YANG et al., "In Vivo and In Vitro Gene Transfer to Mammalian Somatic Cells by Particle Bombardment," <u>Proc. Natl. Acad. Sci. USA</u> 87:9568-9572 (1990).	
	A181	YONEDA et al., "The Antiproliferative Effects of Tyrosine Kinase Inhibitors Tyrphostins on a Human Squamous Cell Carcinoma in Vitro and in Nude Mice," <u>Cancer Research</u> 51:4430-4435 (1991).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.